Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 651 to 675 of 911

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA454	5 July 2017	5 July 2017
Eliglustat for treating type 1 Gaucher disease	HST5	28 June 2017	28 June 2017
Etelcalcetide for treating secondary hyperparathyroidism	TA448	28 June 2017	28 June 2017
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	TA449	28 June 2017	28 June 2017
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	TA450	28 June 2017	28 June 2017
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	TA451	28 June 2017	28 June 2017
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	TA444	24 May 2017	24 May 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	TA445	24 May 2017	24 May 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	TA440	26 April 2017	26 April 2017
Ixekizumab for treating moderate to severe plaque psoriasis	TA442	26 April 2017	26 April 2017
Obeticholic acid for treating primary biliary cholangitis	TA443	26 April 2017	26 April 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)	TA240	14 December 2011	29 March 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)	TA438	29 March 2017	29 March 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal)	TA434	22 March 2017	22 March 2017
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)	TA435	22 March 2017	22 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)	TA436	22 March 2017	22 March 2017
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	TA437	22 March 2017	22 March 2017
Ustekinumab for treating active psoriatic arthritis	TA340	4 June 2015	3 March 2017
Ustekinumab for treating moderate to severe plaque psoriasis	TA180	23 September 2009	3 March 2017
Migalastat for treating Fabry disease	HST4	22 February 2017	22 February 2017
Everolimus for advanced renal cell carcinoma after previous treatment	TA432	22 February 2017	22 February 2017
Apremilast for treating active psoriatic arthritis	TA433	22 February 2017	22 February 2017
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	TA429	25 January 2017	25 January 2017
Sofosbuvir–velpatasvir for treating chronic hepatitis C	TA430	25 January 2017	25 January 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	TA427	11 January 2017	11 January 2017

Results per page

10
25
50
All